Phase I study of CpG ODN(K3), a novel toll-like receptor 9 agonist, for advanced lung cancer: Interim analyses of safety and immunity in subcutaneous injection cohort.

Tomoyuki Otsuka,Sumiyuki Nishida,Masanari Hamaguchi,Takayuki Shibahara,Takayuki Shiroyama,Keiko Kimura,Haruhiko Hirata,Hiroshi Kida,Ken J. Ishii,Atsushi Kumanogoh

Phase I study of CpG ODN(K3), a novel toll-like receptor 9 agonist, for advanced lung cancer: Interim analyses of safety and immunity in subcutaneous injection cohort.

2019

Tomoyuki Otsuka
Sumiyuki Nishida
Masanari Hamaguchi
Takayuki Shibahara
Takayuki Shiroyama
Keiko Kimura
Haruhiko Hirata
Hiroshi Kida
Ken J. Ishii
Atsushi Kumanogoh

126Background: CpG oligodeoxynucleotide (CpG ODN) (K3), a toll-like receptor 9 agonist, is a novel synthetic single-strand DNA immune adjuvant for cancer immunotherapy. CpG ODN(K3) induces the prod...

Keywords:

Toll-Like Receptor 9
Subcutaneous injection
Pathology
CpG Oligodeoxynucleotide
Agonist
Cancer research
Cohort
Interim
Medicine
Lung cancer
Immunity
Immune adjuvant
Cancer immunotherapy
Receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations